An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Occurrence of adverse events by NCI CTCAE grade and associated dose of GDC-0068
Through study completion or early study discontinuation
No
Premal Patel, M.D., Ph.D.
Study Director
Genentech
Spain: Agencia Española de Medicamentos y Productos Sanitarios
PAM4743g
NCT01090960
March 2010
January 2013
Name | Location |
---|